Aclaris Enterprise Value over EBITDA from 2010 to 2024
| ACRS Stock | USD 1.23 0.01 0.82% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (0.25) | Current Value (0.26) | Quarterly Volatility 8.17455072 |
Check Aclaris Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aclaris main balance sheet or income statement drivers, such as Depreciation And Amortization of 819.9 K, Interest Expense of 3.2 M or Selling General Administrative of 21.3 M, as well as many exotic indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0041 or PTB Ratio of 0.67. Aclaris financial statements analysis is a perfect complement when working with Aclaris Therapeutics Valuation or Volatility modules.
Aclaris | Enterprise Value over EBITDA |
About Aclaris Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Aclaris Therapeutics income statement, its balance sheet, and the statement of cash flows. Aclaris Therapeutics investors use historical funamental indicators, such as Aclaris Therapeutics's Enterprise Value over EBITDA, to determine how well the company is positioned to perform in the future. Although Aclaris Therapeutics investors may use each financial statement separately, they are all related. The changes in Aclaris Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aclaris Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Aclaris Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Aclaris Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aclaris Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aclaris Therapeutics' short interest history, or implied volatility extrapolated from Aclaris Therapeutics options trading.
Pair Trading with Aclaris Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aclaris Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aclaris Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Aclaris Stock
| 0.47 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.46 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Aclaris Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aclaris Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aclaris Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aclaris Therapeutics to buy it.
The correlation of Aclaris Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aclaris Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aclaris Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aclaris Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Aclaris Therapeutics Correlation against competitors. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Aclaris Stock analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Aclaris Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.448 | Quarterly Revenue Growth 1.266 | Return On Assets (0.33) | Return On Equity (0.50) |
The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.